APO Research
Talk to an analyst

APO RESEARCH · REPORT

Therapeutic Nuclear Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Therapeutic Nuclear Drug Market Analysis and Forecast 2026-2032

2 January 2026190 pages

Choose your research edition.

Industry ResearchTherapeutic Nuclear Drug Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Therapeutic Nuclear Drug Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Therapeutic Nuclear Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Therapeutic Nuclear Drug Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Therapeutic Nuclear Drug Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Therapeutic Nuclear Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Therapeutic Nuclear Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Therapeutic Nuclear Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Therapeutic Nuclear Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Therapeutic Nuclear Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Therapeutic Nuclear Drug include Novartis, Dongcheng, Bayer, Q BioMed, Mundipharma, Lantheus, Jubilant Radiopharma, International Isotopes and Curium Pharmaceuticals, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Therapeutic Nuclear Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Therapeutic Nuclear Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Therapeutic Nuclear Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Therapeutic Nuclear Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Therapeutic Nuclear Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Therapeutic Nuclear Drug revenue, projected growth trends, production technology, application and end-user industry.

Therapeutic Nuclear Drug Segment by Company

Novartis

Dongcheng

Bayer

Q BioMed

Mundipharma

Lantheus

Jubilant Radiopharma

International Isotopes

Curium Pharmaceuticals

China Isotope & Radiation

Aurobindo Pharma

Therapeutic Nuclear Drug Segment by Type

Lutetium-177

Radium-223

Iodine-131

Other

Therapeutic Nuclear Drug Segment by Application

Lymphoma

Thyroid

Bone Metastasis

Other

Therapeutic Nuclear Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Nuclear Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Nuclear Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Nuclear Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Therapeutic Nuclear Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Therapeutic Nuclear Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Therapeutic Nuclear Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Therapeutic Nuclear Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Lutetium-177 Major Player Table 3. Radium-223 Major Player Table 4. Iodine-131 Major Player Table 5. Other Major Player Table 6. Global Therapeutic Nuclear Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Lymphoma Major Player Table 8. Thyroid Major Player Table 9. Bone Metastasis Major Player Table 10. Other Major Player Table 11. Therapeutic Nuclear Drug Industry Trends Table 12. Therapeutic Nuclear Drug Industry Drivers Table 13. Therapeutic Nuclear Drug Industry Opportunities and Challenges Table 14. Therapeutic Nuclear Drug Industry Restraints Table 15. Global Therapeutic Nuclear Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Therapeutic Nuclear Drug Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Therapeutic Nuclear Drug Market Share by Region (2021-2026) Table 18. Global Therapeutic Nuclear Drug Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Therapeutic Nuclear Drug Market Share by Region (2027-2032) Table 20. Global Therapeutic Nuclear Drug Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Therapeutic Nuclear Drug Revenue Market Share by Players (2021-2026) Table 22. Global Therapeutic Nuclear Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Therapeutic Nuclear Drug Key Players Headquarters & Area Served Table 24. Global Therapeutic Nuclear Drug Players, Product Type & Application Table 25. Global Therapeutic Nuclear Drug Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Therapeutic Nuclear Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Therapeutic Nuclear Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Therapeutic Nuclear Drug Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Therapeutic Nuclear Drug Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Therapeutic Nuclear Drug Revenue Market Share by Type (2021-2026) Table 32. Global Therapeutic Nuclear Drug Revenue Market Share by Type (2027-2032) Table 33. Global Therapeutic Nuclear Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Therapeutic Nuclear Drug Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Therapeutic Nuclear Drug Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Therapeutic Nuclear Drug Revenue Market Share by Application (2021-2026) Table 37. Global Therapeutic Nuclear Drug Revenue Market Share by Application (2027-2032) Table 38. Novartis Company Information Table 39. Novartis Business Overview Table 40. Novartis Therapeutic Nuclear Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Novartis Therapeutic Nuclear Drug Product Portfolio Table 42. Novartis Recent Development Table 43. Dongcheng Company Information Table 44. Dongcheng Business Overview Table 45. Dongcheng Therapeutic Nuclear Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Dongcheng Therapeutic Nuclear Drug Product Portfolio Table 47. Dongcheng Recent Development Table 48. Bayer Company Information Table 49. Bayer Business Overview Table 50. Bayer Therapeutic Nuclear Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Bayer Therapeutic Nuclear Drug Product Portfolio Table 52. Bayer Recent Development Table 53. Q BioMed Company Information Table 54. Q BioMed Business Overview Table 55. Q BioMed Therapeutic Nuclear Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Q BioMed Therapeutic Nuclear Drug Product Portfolio Table 57. Q BioMed Recent Development Table 58. Mundipharma Company Information Table 59. Mundipharma Business Overview Table 60. Mundipharma Therapeutic Nuclear Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Mundipharma Therapeutic Nuclear Drug Product Portfolio Table 62. Mundipharma Recent Development Table 63. Lantheus Company Information Table 64. Lantheus Business Overview Table 65. Lantheus Therapeutic Nuclear Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Lantheus Therapeutic Nuclear Drug Product Portfolio Table 67. Lantheus Recent Development Table 68. Jubilant Radiopharma Company Information Table 69. Jubilant Radiopharma Business Overview Table 70. Jubilant Radiopharma Therapeutic Nuclear Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Jubilant Radiopharma Therapeutic Nuclear Drug Product Portfolio Table 72. Jubilant Radiopharma Recent Development Table 73. International Isotopes Company Information Table 74. International Isotopes Business Overview Table 75. International Isotopes Therapeutic Nuclear Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. International Isotopes Therapeutic Nuclear Drug Product Portfolio Table 77. International Isotopes Recent Development Table 78. Curium Pharmaceuticals Company Information Table 79. Curium Pharmaceuticals Business Overview Table 80. Curium Pharmaceuticals Therapeutic Nuclear Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Curium Pharmaceuticals Therapeutic Nuclear Drug Product Portfolio Table 82. Curium Pharmaceuticals Recent Development Table 83. China Isotope & Radiation Company Information Table 84. China Isotope & Radiation Business Overview Table 85. China Isotope & Radiation Therapeutic Nuclear Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. China Isotope & Radiation Therapeutic Nuclear Drug Product Portfolio Table 87. China Isotope & Radiation Recent Development Table 88. Aurobindo Pharma Company Information Table 89. Aurobindo Pharma Business Overview Table 90. Aurobindo Pharma Therapeutic Nuclear Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Aurobindo Pharma Therapeutic Nuclear Drug Product Portfolio Table 92. Aurobindo Pharma Recent Development Table 93. North America Therapeutic Nuclear Drug Revenue by Type (2021-2026) & (US$ Million) Table 94. North America Therapeutic Nuclear Drug Revenue by Type (2027-2032) & (US$ Million) Table 95. North America Therapeutic Nuclear Drug Revenue by Application (2021-2026) & (US$ Million) Table 96. North America Therapeutic Nuclear Drug Revenue by Application (2027-2032) & (US$ Million) Table 97. North America Therapeutic Nuclear Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 98. North America Therapeutic Nuclear Drug Revenue by Country (2021-2026) & (US$ Million) Table 99. North America Therapeutic Nuclear Drug Revenue by Country (US$ Million) & (2027-2032) Table 100. Europe Therapeutic Nuclear Drug Revenue by Type (2021-2026) & (US$ Million) Table 101. Europe Therapeutic Nuclear Drug Revenue by Type (2027-2032) & (US$ Million) Table 102. Europe Therapeutic Nuclear Drug Revenue by Application (2021-2026) & (US$ Million) Table 103. Europe Therapeutic Nuclear Drug Revenue by Application (2027-2032) & (US$ Million) Table 104. Europe Therapeutic Nuclear Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 105. Europe Therapeutic Nuclear Drug Revenue by Country (2021-2026) & (US$ Million) Table 106. Europe Therapeutic Nuclear Drug Revenue by Country (US$ Million) & (2027-2032) Table 107. China Therapeutic Nuclear Drug Revenue by Type (2021-2026) & (US$ Million) Table 108. China Therapeutic Nuclear Drug Revenue by Type (2027-2032) & (US$ Million) Table 109. China Therapeutic Nuclear Drug Revenue by Application (2021-2026) & (US$ Million) Table 110. China Therapeutic Nuclear Drug Revenue by Application (2027-2032) & (US$ Million) Table 111. Asia Therapeutic Nuclear Drug Revenue by Type (2021-2026) & (US$ Million) Table 112. Asia Therapeutic Nuclear Drug Revenue by Type (2027-2032) & (US$ Million) Table 113. Asia Therapeutic Nuclear Drug Revenue by Application (2021-2026) & (US$ Million) Table 114. Asia Therapeutic Nuclear Drug Revenue by Application (2027-2032) & (US$ Million) Table 115. Asia Therapeutic Nuclear Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 116. Asia Therapeutic Nuclear Drug Revenue by Region (US$ Million) & (2021-2026) Table 117. Asia Therapeutic Nuclear Drug Revenue by Region (US$ Million) & (2027-2032) Table 118. SAMEA Therapeutic Nuclear Drug Revenue by Type (2021-2026) & (US$ Million) Table 119. SAMEA Therapeutic Nuclear Drug Revenue by Type (2027-2032) & (US$ Million) Table 120. SAMEA Therapeutic Nuclear Drug Revenue by Application (2021-2026) & (US$ Million) Table 121. SAMEA Therapeutic Nuclear Drug Revenue by Application (2027-2032) & (US$ Million) Table 122. SAMEA Therapeutic Nuclear Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 123. SAMEA Therapeutic Nuclear Drug Revenue by Country (2021-2026) & (US$ Million) Table 124. SAMEA Therapeutic Nuclear Drug Revenue by Country (US$ Million) & (2027-2032) Table 125. Research Programs/Design for This Report Table 126. Authors List of This Report Table 127. Secondary Sources Table 128. Primary Sources List of Figures Figure 1. Therapeutic Nuclear Drug Image Figure 2. Global Therapeutic Nuclear Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Therapeutic Nuclear Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Lutetium-177 Image Figure 5. Radium-223 Image Figure 6. Iodine-131 Image Figure 7. Other Image Figure 8. Global Therapeutic Nuclear Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Therapeutic Nuclear Drug Market Size Share 2021 VS 2025 VS 2032 Figure 10. Lymphoma Image Figure 11. Thyroid Image Figure 12. Bone Metastasis Image Figure 13. Other Image Figure 14. Global Therapeutic Nuclear Drug Market Size (US$ Million) & (2021-2032) Figure 15. Global Therapeutic Nuclear Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Therapeutic Nuclear Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Therapeutic Nuclear Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Therapeutic Nuclear Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Therapeutic Nuclear Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Therapeutic Nuclear Drug Revenue Market Share by Type (2021-2032) Figure 22. Global Therapeutic Nuclear Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Therapeutic Nuclear Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Therapeutic Nuclear Drug Revenue Market Share by Application (2021-2032) Figure 25. North America Therapeutic Nuclear Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Therapeutic Nuclear Drug Revenue Share by Type (2021-2032) Figure 27. North America Therapeutic Nuclear Drug Revenue Share by Application (2021-2032) Figure 28. North America Therapeutic Nuclear Drug Revenue Share by Country (2021-2032) Figure 29. United States Therapeutic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Therapeutic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Therapeutic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Therapeutic Nuclear Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Therapeutic Nuclear Drug Revenue Share by Type (2021-2032) Figure 34. Europe Therapeutic Nuclear Drug Revenue Share by Application (2021-2032) Figure 35. Europe Therapeutic Nuclear Drug Revenue Share by Country (2021-2032) Figure 36. Germany Therapeutic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Therapeutic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Therapeutic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Therapeutic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Therapeutic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Therapeutic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Therapeutic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Therapeutic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Therapeutic Nuclear Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Therapeutic Nuclear Drug Revenue Share by Type (2021-2032) Figure 46. China Therapeutic Nuclear Drug Revenue Share by Application (2021-2032) Figure 47. Asia Therapeutic Nuclear Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Therapeutic Nuclear Drug Revenue Share by Type (2021-2032) Figure 49. Asia Therapeutic Nuclear Drug Revenue Share by Application (2021-2032) Figure 50. Asia Therapeutic Nuclear Drug Revenue Share by Region (2021-2032) Figure 51. Japan Therapeutic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Therapeutic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Therapeutic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Therapeutic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Therapeutic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Therapeutic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Therapeutic Nuclear Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Therapeutic Nuclear Drug Revenue Share by Type (2021-2032) Figure 59. SAMEA Therapeutic Nuclear Drug Revenue Share by Application (2021-2032) Figure 60. SAMEA Therapeutic Nuclear Drug Revenue Share by Country (2021-2032) Figure 61. Brazil Therapeutic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Therapeutic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Therapeutic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Therapeutic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Therapeutic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Therapeutic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Therapeutic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Therapeutic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Therapeutic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Therapeutic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Therapeutic Nuclear Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Lutetium-177
  • Radium-223
  • Iodine-131
  • Other
Applications
  • Lymphoma
  • Thyroid
  • Bone Metastasis
  • Other
Companies covered
  • Novartis
  • Dongcheng
  • Bayer
  • Q BioMed
  • Mundipharma
  • Lantheus
  • Jubilant Radiopharma
  • International Isotopes
  • Curium Pharmaceuticals
  • China Isotope & Radiation
  • Aurobindo Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Therapeutic Nuclear Drug Market by Type
  3. 1.2.1 Global Therapeutic Nuclear Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Lutetium-177
  5. 1.2.3 Radium-223
  6. 1.2.4 Iodine-131
  7. 1.2.5 Other
  8. 1.3 Therapeutic Nuclear Drug Market by Application
  9. 1.3.1 Global Therapeutic Nuclear Drug Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Lymphoma
  11. 1.3.3 Thyroid
  12. 1.3.4 Bone Metastasis
  13. 1.3.5 Other
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Therapeutic Nuclear Drug Market Dynamics
  1. 2.1 Therapeutic Nuclear Drug Industry Trends
  2. 2.2 Therapeutic Nuclear Drug Industry Drivers
  3. 2.3 Therapeutic Nuclear Drug Industry Opportunities and Challenges
  4. 2.4 Therapeutic Nuclear Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Therapeutic Nuclear Drug Market Perspective (2021-2032)
  2. 3.2 Global Therapeutic Nuclear Drug Growth Trends by Region
  3. 3.2.1 Global Therapeutic Nuclear Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Therapeutic Nuclear Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Therapeutic Nuclear Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Therapeutic Nuclear Drug Revenue by Players
  2. 4.1.1 Global Therapeutic Nuclear Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Therapeutic Nuclear Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Therapeutic Nuclear Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Therapeutic Nuclear Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Therapeutic Nuclear Drug Key Players Headquarters & Area Served
  7. 4.4 Global Therapeutic Nuclear Drug Players, Product Type & Application
  8. 4.5 Global Therapeutic Nuclear Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Therapeutic Nuclear Drug Market CR5 and HHI
  11. 4.6.3 2025 Therapeutic Nuclear Drug Tier 1, Tier 2, and Tier 3
5 Therapeutic Nuclear Drug Market Size by Type
  1. 5.1 Global Therapeutic Nuclear Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Therapeutic Nuclear Drug Revenue by Type (2021-2032)
  3. 5.3 Global Therapeutic Nuclear Drug Revenue Market Share by Type (2021-2032)
6 Therapeutic Nuclear Drug Market Size by Application
  1. 6.1 Global Therapeutic Nuclear Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Therapeutic Nuclear Drug Revenue by Application (2021-2032)
  3. 6.3 Global Therapeutic Nuclear Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Novartis
  2. 7.1.1 Novartis Company Information
  3. 7.1.2 Novartis Business Overview
  4. 7.1.3 Novartis Therapeutic Nuclear Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Novartis Therapeutic Nuclear Drug Product Portfolio
  6. 7.1.5 Novartis Recent Developments
  7. 7.2 Dongcheng
  8. 7.2.1 Dongcheng Company Information
  9. 7.2.2 Dongcheng Business Overview
  10. 7.2.3 Dongcheng Therapeutic Nuclear Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Dongcheng Therapeutic Nuclear Drug Product Portfolio
  12. 7.2.5 Dongcheng Recent Developments
  13. 7.3 Bayer
  14. 7.3.1 Bayer Company Information
  15. 7.3.2 Bayer Business Overview
  16. 7.3.3 Bayer Therapeutic Nuclear Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Bayer Therapeutic Nuclear Drug Product Portfolio
  18. 7.3.5 Bayer Recent Developments
  19. 7.4 Q BioMed
  20. 7.4.1 Q BioMed Company Information
  21. 7.4.2 Q BioMed Business Overview
  22. 7.4.3 Q BioMed Therapeutic Nuclear Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Q BioMed Therapeutic Nuclear Drug Product Portfolio
  24. 7.4.5 Q BioMed Recent Developments
  25. 7.5 Mundipharma
  26. 7.5.1 Mundipharma Company Information
  27. 7.5.2 Mundipharma Business Overview
  28. 7.5.3 Mundipharma Therapeutic Nuclear Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Mundipharma Therapeutic Nuclear Drug Product Portfolio
  30. 7.5.5 Mundipharma Recent Developments
  31. 7.6 Lantheus
  32. 7.6.1 Lantheus Company Information
  33. 7.6.2 Lantheus Business Overview
  34. 7.6.3 Lantheus Therapeutic Nuclear Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Lantheus Therapeutic Nuclear Drug Product Portfolio
  36. 7.6.5 Lantheus Recent Developments
  37. 7.7 Jubilant Radiopharma
  38. 7.7.1 Jubilant Radiopharma Company Information
  39. 7.7.2 Jubilant Radiopharma Business Overview
  40. 7.7.3 Jubilant Radiopharma Therapeutic Nuclear Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Jubilant Radiopharma Therapeutic Nuclear Drug Product Portfolio
  42. 7.7.5 Jubilant Radiopharma Recent Developments
  43. 7.8 International Isotopes
  44. 7.8.1 International Isotopes Company Information
  45. 7.8.2 International Isotopes Business Overview
  46. 7.8.3 International Isotopes Therapeutic Nuclear Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 International Isotopes Therapeutic Nuclear Drug Product Portfolio
  48. 7.8.5 International Isotopes Recent Developments
  49. 7.9 Curium Pharmaceuticals
  50. 7.9.1 Curium Pharmaceuticals Company Information
  51. 7.9.2 Curium Pharmaceuticals Business Overview
  52. 7.9.3 Curium Pharmaceuticals Therapeutic Nuclear Drug Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Curium Pharmaceuticals Therapeutic Nuclear Drug Product Portfolio
  54. 7.9.5 Curium Pharmaceuticals Recent Developments
  55. 7.10 China Isotope & Radiation
  56. 7.10.1 China Isotope & Radiation Company Information
  57. 7.10.2 China Isotope & Radiation Business Overview
  58. 7.10.3 China Isotope & Radiation Therapeutic Nuclear Drug Revenue and Gross Margin (2021-2026)
  59. 7.10.4 China Isotope & Radiation Therapeutic Nuclear Drug Product Portfolio
  60. 7.10.5 China Isotope & Radiation Recent Developments
  61. 7.11 Aurobindo Pharma
  62. 7.11.1 Aurobindo Pharma Company Information
  63. 7.11.2 Aurobindo Pharma Business Overview
  64. 7.11.3 Aurobindo Pharma Therapeutic Nuclear Drug Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Aurobindo Pharma Therapeutic Nuclear Drug Product Portfolio
  66. 7.11.5 Aurobindo Pharma Recent Developments
8 North America
  1. 8.1 North America Therapeutic Nuclear Drug Revenue (2021-2032)
  2. 8.2 North America Therapeutic Nuclear Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Therapeutic Nuclear Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Therapeutic Nuclear Drug Revenue by Type (2027-2032)
  5. 8.3 North America Therapeutic Nuclear Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Therapeutic Nuclear Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Therapeutic Nuclear Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Therapeutic Nuclear Drug Revenue by Application (2027-2032)
  9. 8.5 North America Therapeutic Nuclear Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Therapeutic Nuclear Drug Revenue by Country
  11. 8.6.1 North America Therapeutic Nuclear Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Therapeutic Nuclear Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Therapeutic Nuclear Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Therapeutic Nuclear Drug Revenue (2021-2032)
  2. 9.2 Europe Therapeutic Nuclear Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Therapeutic Nuclear Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Therapeutic Nuclear Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Therapeutic Nuclear Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Therapeutic Nuclear Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Therapeutic Nuclear Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Therapeutic Nuclear Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Therapeutic Nuclear Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Therapeutic Nuclear Drug Revenue by Country
  11. 9.6.1 Europe Therapeutic Nuclear Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Therapeutic Nuclear Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Therapeutic Nuclear Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Therapeutic Nuclear Drug Revenue (2021-2032)
  2. 10.2 China Therapeutic Nuclear Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Therapeutic Nuclear Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Therapeutic Nuclear Drug Revenue by Type (2027-2032)
  5. 10.3 China Therapeutic Nuclear Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Therapeutic Nuclear Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Therapeutic Nuclear Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Therapeutic Nuclear Drug Revenue by Application (2027-2032)
  9. 10.5 China Therapeutic Nuclear Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Therapeutic Nuclear Drug Revenue (2021-2032)
  2. 11.2 Asia Therapeutic Nuclear Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Therapeutic Nuclear Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Therapeutic Nuclear Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Therapeutic Nuclear Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Therapeutic Nuclear Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Therapeutic Nuclear Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Therapeutic Nuclear Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Therapeutic Nuclear Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Therapeutic Nuclear Drug Revenue by Country
  11. 11.6.1 Asia Therapeutic Nuclear Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Therapeutic Nuclear Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Therapeutic Nuclear Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Therapeutic Nuclear Drug Revenue (2021-2032)
  2. 12.2 SAMEA Therapeutic Nuclear Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Therapeutic Nuclear Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Therapeutic Nuclear Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Therapeutic Nuclear Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Therapeutic Nuclear Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Therapeutic Nuclear Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Therapeutic Nuclear Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Therapeutic Nuclear Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Therapeutic Nuclear Drug Revenue by Country
  11. 12.6.1 SAMEA Therapeutic Nuclear Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Therapeutic Nuclear Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Therapeutic Nuclear Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst